Sarcopenia is a prognostic factor for TKIs in metastatic thyroid carcinomas
Purpose Among patients with various cancers receiving anticancer drugs, sarcopenia is associated with poor survival and treatment outcomes. We conducted an observational study using skeletal muscle index (SMI) evaluation to investigate the association between sarcopenia and treatment outcomes of tyr...
Gespeichert in:
| Veröffentlicht in: | Endocrine 2020-04, Vol.68 (1), p.132-137 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 137 |
|---|---|
| container_issue | 1 |
| container_start_page | 132 |
| container_title | Endocrine |
| container_volume | 68 |
| creator | Yamazaki, Haruhiko Sugino, Kiminori Matsuzu, Kenichi Masaki, Chie Akaishi, Junko Hames, Kiyomi Tomoda, Chisato Suzuki, Akifumi Uruno, Takashi Ohkuwa, Keiko Kitagawa, Wataru Nagahama, Mitsuji Masuda, Munetaka Ito, Kouichi |
| description | Purpose
Among patients with various cancers receiving anticancer drugs, sarcopenia is associated with poor survival and treatment outcomes. We conducted an observational study using skeletal muscle index (SMI) evaluation to investigate the association between sarcopenia and treatment outcomes of tyrosine kinase inhibitors (TKIs) in metastatic thyroid cancer patients.
Methods
We included 54 patients (19 men, 35 women; age, 66.5 ± 10.9 years) with differentiated thyroid carcinoma (DTC) or medullary thyroid carcinoma (MTC). The records of patients with metastatic DTC and MTC treated with TKIs were retrospectively reviewed. Patients were divided into sarcopenia and non-sarcopenia groups based on SMI. The SMI cutoff values for sarcopenia were 42 and 38 (cm
2
/m
2
) for males and females, respectively. Thirty-three patients had sarcopenia before TKI treatment.
Results
The sarcopenia group had more females and a lower body mass index. The median progression-free survival (PFS) durations were 13.6 (95% confidence interval (CI): 6.1–29.9) and 41.9 (95% CI: 25.2–not estimable) months in the sarcopenia and non-sarcopenia groups (
p
=
0.017), respectively. Univariate analysis showed that sarcopenia was significantly associated with PFS (
p
=
0.037). Sex, age, and performance status did not affect PFS. Multivariate analysis showed that sarcopenia was the only independent prognostic factor for PFS (hazard ratio: 2.488, 95% CI: 1.058–5.846,
p
=
0.037).
Conclusions
Sarcopenia could be a predictive factor of TKI treatment outcomes in patients with metastatic thyroid cancer as well as intervention target to improve prognosis. Further prospective investigations are needed to confirm these preliminary data. |
| doi_str_mv | 10.1007/s12020-019-02162-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2330063306</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2390186426</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-72c87069487e70459276a359d6ed7959052a257a12a29797650004278907141c3</originalsourceid><addsrcrecordid>eNp9kE9LAzEQxYMotla_gAdZ8OJldZLdJJujFP-UFjxYwVuI2Wzd0t3UZAvtt3dqq4IHA8kkvN-8DI-QcwrXFEDeRMqAQQpUpcCoYOn6gPQp5_hE_RDvGecpQPHaIycxzgEYY0Iek15GC8Fx9cn42QTrl66tTVLHxCTL4Getj11tk8rYzoekwj0dj2JSt0njOhM7s1W7903wdZlYNKhb35h4So4qs4jubF8H5OX-bjp8TCdPD6Ph7SS1meRdKpktJAiVF9JJyLliUpiMq1K4UiqugDPDuDQUi5JKCg4AOZOFAklzarMBudr54qwfKxc73dTRusXCtM6vomZZBiDwEIhe_kHnfhVanA4pBRhDzrYU21E2-BiDq_Qy1I0JG01Bb6PWu6g1Rq2_otZrbLrYW6_eGlf-tHxni0C2AyJK7cyF37__sf0EwiGGaQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2390186426</pqid></control><display><type>article</type><title>Sarcopenia is a prognostic factor for TKIs in metastatic thyroid carcinomas</title><source>SpringerLink Journals - AutoHoldings</source><creator>Yamazaki, Haruhiko ; Sugino, Kiminori ; Matsuzu, Kenichi ; Masaki, Chie ; Akaishi, Junko ; Hames, Kiyomi ; Tomoda, Chisato ; Suzuki, Akifumi ; Uruno, Takashi ; Ohkuwa, Keiko ; Kitagawa, Wataru ; Nagahama, Mitsuji ; Masuda, Munetaka ; Ito, Kouichi</creator><creatorcontrib>Yamazaki, Haruhiko ; Sugino, Kiminori ; Matsuzu, Kenichi ; Masaki, Chie ; Akaishi, Junko ; Hames, Kiyomi ; Tomoda, Chisato ; Suzuki, Akifumi ; Uruno, Takashi ; Ohkuwa, Keiko ; Kitagawa, Wataru ; Nagahama, Mitsuji ; Masuda, Munetaka ; Ito, Kouichi</creatorcontrib><description>Purpose
Among patients with various cancers receiving anticancer drugs, sarcopenia is associated with poor survival and treatment outcomes. We conducted an observational study using skeletal muscle index (SMI) evaluation to investigate the association between sarcopenia and treatment outcomes of tyrosine kinase inhibitors (TKIs) in metastatic thyroid cancer patients.
Methods
We included 54 patients (19 men, 35 women; age, 66.5 ± 10.9 years) with differentiated thyroid carcinoma (DTC) or medullary thyroid carcinoma (MTC). The records of patients with metastatic DTC and MTC treated with TKIs were retrospectively reviewed. Patients were divided into sarcopenia and non-sarcopenia groups based on SMI. The SMI cutoff values for sarcopenia were 42 and 38 (cm
2
/m
2
) for males and females, respectively. Thirty-three patients had sarcopenia before TKI treatment.
Results
The sarcopenia group had more females and a lower body mass index. The median progression-free survival (PFS) durations were 13.6 (95% confidence interval (CI): 6.1–29.9) and 41.9 (95% CI: 25.2–not estimable) months in the sarcopenia and non-sarcopenia groups (
p
=
0.017), respectively. Univariate analysis showed that sarcopenia was significantly associated with PFS (
p
=
0.037). Sex, age, and performance status did not affect PFS. Multivariate analysis showed that sarcopenia was the only independent prognostic factor for PFS (hazard ratio: 2.488, 95% CI: 1.058–5.846,
p
=
0.037).
Conclusions
Sarcopenia could be a predictive factor of TKI treatment outcomes in patients with metastatic thyroid cancer as well as intervention target to improve prognosis. Further prospective investigations are needed to confirm these preliminary data.</description><identifier>ISSN: 1355-008X</identifier><identifier>EISSN: 1559-0100</identifier><identifier>DOI: 10.1007/s12020-019-02162-x</identifier><identifier>PMID: 31865555</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Antineoplastic drugs ; Antitumor agents ; Body mass index ; Clinical outcomes ; Diabetes ; Endocrinology ; Humanities and Social Sciences ; Internal Medicine ; Medical prognosis ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; multidisciplinary ; Multivariate analysis ; Original Article ; Protein-tyrosine kinase ; Sarcopenia ; Science ; Skeletal muscle ; Survival ; Thyroid cancer ; Thyroid carcinoma</subject><ispartof>Endocrine, 2020-04, Vol.68 (1), p.132-137</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-72c87069487e70459276a359d6ed7959052a257a12a29797650004278907141c3</citedby><cites>FETCH-LOGICAL-c375t-72c87069487e70459276a359d6ed7959052a257a12a29797650004278907141c3</cites><orcidid>0000-0002-6640-3529</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12020-019-02162-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12020-019-02162-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31865555$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamazaki, Haruhiko</creatorcontrib><creatorcontrib>Sugino, Kiminori</creatorcontrib><creatorcontrib>Matsuzu, Kenichi</creatorcontrib><creatorcontrib>Masaki, Chie</creatorcontrib><creatorcontrib>Akaishi, Junko</creatorcontrib><creatorcontrib>Hames, Kiyomi</creatorcontrib><creatorcontrib>Tomoda, Chisato</creatorcontrib><creatorcontrib>Suzuki, Akifumi</creatorcontrib><creatorcontrib>Uruno, Takashi</creatorcontrib><creatorcontrib>Ohkuwa, Keiko</creatorcontrib><creatorcontrib>Kitagawa, Wataru</creatorcontrib><creatorcontrib>Nagahama, Mitsuji</creatorcontrib><creatorcontrib>Masuda, Munetaka</creatorcontrib><creatorcontrib>Ito, Kouichi</creatorcontrib><title>Sarcopenia is a prognostic factor for TKIs in metastatic thyroid carcinomas</title><title>Endocrine</title><addtitle>Endocrine</addtitle><addtitle>Endocrine</addtitle><description>Purpose
Among patients with various cancers receiving anticancer drugs, sarcopenia is associated with poor survival and treatment outcomes. We conducted an observational study using skeletal muscle index (SMI) evaluation to investigate the association between sarcopenia and treatment outcomes of tyrosine kinase inhibitors (TKIs) in metastatic thyroid cancer patients.
Methods
We included 54 patients (19 men, 35 women; age, 66.5 ± 10.9 years) with differentiated thyroid carcinoma (DTC) or medullary thyroid carcinoma (MTC). The records of patients with metastatic DTC and MTC treated with TKIs were retrospectively reviewed. Patients were divided into sarcopenia and non-sarcopenia groups based on SMI. The SMI cutoff values for sarcopenia were 42 and 38 (cm
2
/m
2
) for males and females, respectively. Thirty-three patients had sarcopenia before TKI treatment.
Results
The sarcopenia group had more females and a lower body mass index. The median progression-free survival (PFS) durations were 13.6 (95% confidence interval (CI): 6.1–29.9) and 41.9 (95% CI: 25.2–not estimable) months in the sarcopenia and non-sarcopenia groups (
p
=
0.017), respectively. Univariate analysis showed that sarcopenia was significantly associated with PFS (
p
=
0.037). Sex, age, and performance status did not affect PFS. Multivariate analysis showed that sarcopenia was the only independent prognostic factor for PFS (hazard ratio: 2.488, 95% CI: 1.058–5.846,
p
=
0.037).
Conclusions
Sarcopenia could be a predictive factor of TKI treatment outcomes in patients with metastatic thyroid cancer as well as intervention target to improve prognosis. Further prospective investigations are needed to confirm these preliminary data.</description><subject>Antineoplastic drugs</subject><subject>Antitumor agents</subject><subject>Body mass index</subject><subject>Clinical outcomes</subject><subject>Diabetes</subject><subject>Endocrinology</subject><subject>Humanities and Social Sciences</subject><subject>Internal Medicine</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>multidisciplinary</subject><subject>Multivariate analysis</subject><subject>Original Article</subject><subject>Protein-tyrosine kinase</subject><subject>Sarcopenia</subject><subject>Science</subject><subject>Skeletal muscle</subject><subject>Survival</subject><subject>Thyroid cancer</subject><subject>Thyroid carcinoma</subject><issn>1355-008X</issn><issn>1559-0100</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kE9LAzEQxYMotla_gAdZ8OJldZLdJJujFP-UFjxYwVuI2Wzd0t3UZAvtt3dqq4IHA8kkvN-8DI-QcwrXFEDeRMqAQQpUpcCoYOn6gPQp5_hE_RDvGecpQPHaIycxzgEYY0Iek15GC8Fx9cn42QTrl66tTVLHxCTL4Getj11tk8rYzoekwj0dj2JSt0njOhM7s1W7903wdZlYNKhb35h4So4qs4jubF8H5OX-bjp8TCdPD6Ph7SS1meRdKpktJAiVF9JJyLliUpiMq1K4UiqugDPDuDQUi5JKCg4AOZOFAklzarMBudr54qwfKxc73dTRusXCtM6vomZZBiDwEIhe_kHnfhVanA4pBRhDzrYU21E2-BiDq_Qy1I0JG01Bb6PWu6g1Rq2_otZrbLrYW6_eGlf-tHxni0C2AyJK7cyF37__sf0EwiGGaQ</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Yamazaki, Haruhiko</creator><creator>Sugino, Kiminori</creator><creator>Matsuzu, Kenichi</creator><creator>Masaki, Chie</creator><creator>Akaishi, Junko</creator><creator>Hames, Kiyomi</creator><creator>Tomoda, Chisato</creator><creator>Suzuki, Akifumi</creator><creator>Uruno, Takashi</creator><creator>Ohkuwa, Keiko</creator><creator>Kitagawa, Wataru</creator><creator>Nagahama, Mitsuji</creator><creator>Masuda, Munetaka</creator><creator>Ito, Kouichi</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6640-3529</orcidid></search><sort><creationdate>20200401</creationdate><title>Sarcopenia is a prognostic factor for TKIs in metastatic thyroid carcinomas</title><author>Yamazaki, Haruhiko ; Sugino, Kiminori ; Matsuzu, Kenichi ; Masaki, Chie ; Akaishi, Junko ; Hames, Kiyomi ; Tomoda, Chisato ; Suzuki, Akifumi ; Uruno, Takashi ; Ohkuwa, Keiko ; Kitagawa, Wataru ; Nagahama, Mitsuji ; Masuda, Munetaka ; Ito, Kouichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-72c87069487e70459276a359d6ed7959052a257a12a29797650004278907141c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antineoplastic drugs</topic><topic>Antitumor agents</topic><topic>Body mass index</topic><topic>Clinical outcomes</topic><topic>Diabetes</topic><topic>Endocrinology</topic><topic>Humanities and Social Sciences</topic><topic>Internal Medicine</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>multidisciplinary</topic><topic>Multivariate analysis</topic><topic>Original Article</topic><topic>Protein-tyrosine kinase</topic><topic>Sarcopenia</topic><topic>Science</topic><topic>Skeletal muscle</topic><topic>Survival</topic><topic>Thyroid cancer</topic><topic>Thyroid carcinoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamazaki, Haruhiko</creatorcontrib><creatorcontrib>Sugino, Kiminori</creatorcontrib><creatorcontrib>Matsuzu, Kenichi</creatorcontrib><creatorcontrib>Masaki, Chie</creatorcontrib><creatorcontrib>Akaishi, Junko</creatorcontrib><creatorcontrib>Hames, Kiyomi</creatorcontrib><creatorcontrib>Tomoda, Chisato</creatorcontrib><creatorcontrib>Suzuki, Akifumi</creatorcontrib><creatorcontrib>Uruno, Takashi</creatorcontrib><creatorcontrib>Ohkuwa, Keiko</creatorcontrib><creatorcontrib>Kitagawa, Wataru</creatorcontrib><creatorcontrib>Nagahama, Mitsuji</creatorcontrib><creatorcontrib>Masuda, Munetaka</creatorcontrib><creatorcontrib>Ito, Kouichi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Endocrine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamazaki, Haruhiko</au><au>Sugino, Kiminori</au><au>Matsuzu, Kenichi</au><au>Masaki, Chie</au><au>Akaishi, Junko</au><au>Hames, Kiyomi</au><au>Tomoda, Chisato</au><au>Suzuki, Akifumi</au><au>Uruno, Takashi</au><au>Ohkuwa, Keiko</au><au>Kitagawa, Wataru</au><au>Nagahama, Mitsuji</au><au>Masuda, Munetaka</au><au>Ito, Kouichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sarcopenia is a prognostic factor for TKIs in metastatic thyroid carcinomas</atitle><jtitle>Endocrine</jtitle><stitle>Endocrine</stitle><addtitle>Endocrine</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>68</volume><issue>1</issue><spage>132</spage><epage>137</epage><pages>132-137</pages><issn>1355-008X</issn><eissn>1559-0100</eissn><abstract>Purpose
Among patients with various cancers receiving anticancer drugs, sarcopenia is associated with poor survival and treatment outcomes. We conducted an observational study using skeletal muscle index (SMI) evaluation to investigate the association between sarcopenia and treatment outcomes of tyrosine kinase inhibitors (TKIs) in metastatic thyroid cancer patients.
Methods
We included 54 patients (19 men, 35 women; age, 66.5 ± 10.9 years) with differentiated thyroid carcinoma (DTC) or medullary thyroid carcinoma (MTC). The records of patients with metastatic DTC and MTC treated with TKIs were retrospectively reviewed. Patients were divided into sarcopenia and non-sarcopenia groups based on SMI. The SMI cutoff values for sarcopenia were 42 and 38 (cm
2
/m
2
) for males and females, respectively. Thirty-three patients had sarcopenia before TKI treatment.
Results
The sarcopenia group had more females and a lower body mass index. The median progression-free survival (PFS) durations were 13.6 (95% confidence interval (CI): 6.1–29.9) and 41.9 (95% CI: 25.2–not estimable) months in the sarcopenia and non-sarcopenia groups (
p
=
0.017), respectively. Univariate analysis showed that sarcopenia was significantly associated with PFS (
p
=
0.037). Sex, age, and performance status did not affect PFS. Multivariate analysis showed that sarcopenia was the only independent prognostic factor for PFS (hazard ratio: 2.488, 95% CI: 1.058–5.846,
p
=
0.037).
Conclusions
Sarcopenia could be a predictive factor of TKI treatment outcomes in patients with metastatic thyroid cancer as well as intervention target to improve prognosis. Further prospective investigations are needed to confirm these preliminary data.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>31865555</pmid><doi>10.1007/s12020-019-02162-x</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-6640-3529</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1355-008X |
| ispartof | Endocrine, 2020-04, Vol.68 (1), p.132-137 |
| issn | 1355-008X 1559-0100 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2330063306 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Antineoplastic drugs Antitumor agents Body mass index Clinical outcomes Diabetes Endocrinology Humanities and Social Sciences Internal Medicine Medical prognosis Medicine Medicine & Public Health Metastases Metastasis multidisciplinary Multivariate analysis Original Article Protein-tyrosine kinase Sarcopenia Science Skeletal muscle Survival Thyroid cancer Thyroid carcinoma |
| title | Sarcopenia is a prognostic factor for TKIs in metastatic thyroid carcinomas |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T06%3A26%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sarcopenia%20is%20a%20prognostic%20factor%20for%20TKIs%20in%20metastatic%20thyroid%20carcinomas&rft.jtitle=Endocrine&rft.au=Yamazaki,%20Haruhiko&rft.date=2020-04-01&rft.volume=68&rft.issue=1&rft.spage=132&rft.epage=137&rft.pages=132-137&rft.issn=1355-008X&rft.eissn=1559-0100&rft_id=info:doi/10.1007/s12020-019-02162-x&rft_dat=%3Cproquest_cross%3E2390186426%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2390186426&rft_id=info:pmid/31865555&rfr_iscdi=true |